Terns Pharmaceuticals Positioned for Success With Promising Oral Therapy TERN-601 Amid Novo Nordisk's Setback
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $14
Mizuho Securities Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
Merck-Hansoh Deal for Oral GLP-1 Hurts Obesity Drug Developers
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
